2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
246
Precursor Cell Lymphoblastic Leukemia-Lymphoma
147
Myelodysplastic Syndromes
144
Leukemia, Lymphocytic, Chronic, B-Cell
140
Leukemia
128
Multiple Myeloma
118
Lymphoma
116
Lymphoma, Non-Hodgkin
112
Recurrence
80
Hematologic Neoplasms
77
Melanoma
68
Hodgkin Disease
68
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
67
Lymphoma, B-Cell
61
Lymphoma, Mantle-Cell
52
Lymphoma, Large B-Cell, Diffuse
50
Lymphoma, Follicular
50
Burkitt Lymphoma
41
Ovarian Neoplasms
40
Neoplasms
39
Myeloproliferative Disorders
39
Neoplasm Metastasis
34
Lymphoma, B-Cell, Marginal Zone
30
Graft vs Host Disease
29
Neoplasms, Plasma Cell
28
Carcinoma, Non-Small-Cell Lung
27
Breast Neoplasms
27
Leukemia, Biphenotypic, Acute
25
Primary Myelofibrosis
24
Anemia, Refractory, with Excess of Blasts
23
Interventions
Cyclophosphamide
8
dinutuximab
7
Magnetic Resonance Spectroscopy
7
Topotecan
6
Doxorubicin
6
sargramostim
5
Vincristine
5
Stem Cell Transplantation
5
Radiation
5
Platinum
5
Melphalan
5
Isotretinoin
5
Colony-Stimulating Factors
5
Cisplatin
5
Biopsy
5
1,2-diaminocyclohexaneplatinum II citrate
5
Temozolomide
4
Specimen Handling
4
Irinotecan
4
Etoposide
4
Congresses as Topic
4
Carboplatin
4
Thiotepa
3
Busulfan
3
3-Iodobenzylguanidine
3
etoposide phosphate
2
Razoxane
2
Dexrazoxane
2
temsirolimus
1
lorlatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ganglioneuroblastoma
×
fludarabine
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled